OncoMatch/Clinical Trials/NCT07397338
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Is NCT07397338 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for advanced solid tumors.
Treatment: Daraxonrasib · Elironrasib · Zoldonrasib · Ivonescimab · Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) · cetuximab (Cohort C2 Only) · Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) · Daraxonrasib (Cohort B1 only) — The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Biomarker criteria
Required: HRAS mutation
Required: KRAS mutation
Required: NRAS mutation
Disease stage
Metastatic disease required
locally advanced or metastatic solid tumor malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — advanced/metastatic
Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration)
Lab requirements
Blood counts
adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Kidney function
adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Liver function
adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Adequate organ function (bone marrow, liver, kidney, coagulation, endocrine)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Eastern Connecticut Hematology and Oncology Associates · Norwich, Connecticut
- Tennessee Oncology · Nashville, Tennessee
- NEXT Dallas · Irving, Texas
- NEXT Oncology · San Antonio, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify